Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.58 |
| ▸ | CTSS | P25774 | 2/20 | 0.58 |
| ▸ | PPARA | Q07869 | 9/20 | 0.56 |
| ▸ | PPARG | P37231 | 8/20 | 0.54 |
| ▸ | PPARD | Q03181 | 2/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8316046 | 1.00 | CTSK (0.58) | CTSKCTSSPPARAPPARGPPARD | |
| SCHEMBL3773563 | 1.00 | CTSK (0.58) | CTSKCTSSPPARAPPARGPPARD | |
| SCHEMBL31407745 | 0.92 | CTSK (0.56) | CTSKCTSSPPARAPPARGPPARD | |
| SCHEMBL29055935 | 0.92 | CTSK (0.56) | CTSKCTSSPPARAPPARGPPARD | |
| SCHEMBL13726663 | 0.91 | CTSK (0.53) | CTSKCTSSPPARAPPARGPPARD | |
| SCHEMBL12305799 | 0.89 | PPARA (0.62) | CTSKCTSSPPARAPPARGPPARD | |
| SCHEMBL21409154 | 0.89 | PPARA (0.62) | CTSKCTSSPPARAPPARGPPARD | |
| SCHEMBL10151227 | 0.89 | CTSK (0.58) | CTSKCTSSPPARAPPARGPPARD | |
| SCHEMBL12305804 | 0.89 | CTSK (0.58) | CTSKCTSSPPARAPPARGPPARD | |
| SCHEMBL8241451 | 0.89 | PPARA (0.62) | CTSKCTSSPPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| EP-4097096-A2 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| CN-1067384-C | Adhesion receptor antagonists | MERCK PATENT GMBH (DE) | 2001-06-20 | — | — | CN | disclosed |
| CN-1130626-A | Adhesion receptor antagonists | MERCK PATENT GMBH (DE) | 1996-09-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | CTSK 2376/4885CTSS 2064/4885PPARA 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.